Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.
종목 코드 MURA
회사 이름Mural Oncology PLC
상장일Nov 03, 2023
CEOOwen Hughes (Owen)
직원 수116
유형Ordinary Share
회계 연도 종료Nov 03
주소10 Earlsfort Terrace
도시DUBLIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Ireland
우편 번호D02 T380
전화35319058020
웹사이트https://www.muraloncology.com/
종목 코드 MURA
상장일Nov 03, 2023
CEOOwen Hughes (Owen)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음